Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48

Abstract Background Two of the three recently approved β-lactam agent (BL)/β-lactamase inhibitor (BLI) combinations have higher CLSI susceptibility breakpoints (ceftazidime/avibactam 8 mg/L; meropenem/vaborbactam 4 mg/L) compared with the BL alone (ceftazidime 4 mg/L; meropenem 1 mg/L). This can lea...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of antimicrobial chemotherapy 2023-03, Vol.78 (3), p.636-645
Hauptverfasser:	Asempa, Tomefa E, Kois, Abigail K, Gill, Christian M, Nicolau, David P
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anti-Bacterial Agents - pharmacology Azabicyclo Compounds - pharmacology beta-Lactamase Inhibitors - pharmacology beta-Lactamases - genetics Ceftazidime - pharmacology Drug Combinations Genotype Imipenem - pharmacology Lactams Meropenem - pharmacology Mice Microbial Sensitivity Tests Phenotype
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!